Immune checkpoint blockade and targeted therapies in esophageal cancer Review
| Authors: | Yang, J.; Janjigian, Y. Y. |
| Review Title: | Immune checkpoint blockade and targeted therapies in esophageal cancer |
| Abstract: | Advanced esophageal cancer has one of the lowest 5-year survival rates. Historically, treatment options have been limited to cytotoxic chemotherapy but recent trials have established a key role for immune checkpoint inhibitors. Chemotherapy plus nivolumab or pembrolizumab now represents the new standard of care frontline regimen for both esophageal adenocarcinoma and squamous cell carcinoma. Advances in targeting HER2 and other molecular targets have also expanded our therapeutic landscape. This article aims to provide an overview of recent advances in immunotherapy and targeted therapy for esophageal cancer as well as summarize ongoing clinical trials and future directions. Copyright © 2022. Published by Elsevier Inc. |
| Keywords: | monoclonal antibody; antibodies, monoclonal; immunotherapy; targeted therapy; esophageal adenocarcinoma; esophagus tumor; esophageal neoplasms; esophageal cancer; esophageal squamous cell carcinoma; nivolumab; humans; human; immune checkpoint inhibitors |
| Journal Title: | Thoracic Surgery Clinics |
| Volume: | 32 |
| Issue: | 4 |
| ISSN: | 1547-4127 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2022-11-01 |
| Start Page: | 467 |
| End Page: | 478 |
| Language: | English |
| DOI: | 10.1016/j.thorsurg.2022.07.002 |
| PUBMED: | 36266034 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 November 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work